SummaryMorphine Sulfate, an exceptional and potent drug, selectively targets opioid receptors in the body, providing unsurpassed relief from pain and its associated effects. As an agonist, it stimulates mu, kappa, and delta opioid receptors, binding and activating these specific receptors, and serving as an impeccable option for managing severe pain, such as that resulting from cancer or post-surgery. The drug underwent extensive regulatory scrutiny and was granted approval in September 1984. Since then, it has become a widely used and trusted means of pain management, despite being a controlled substance that requires prescriptions from healthcare providers due to its potential for abuse and addiction. Patients should be mindful of the range of potential side effects associated with Morphine Sulfate, including dizziness, nausea, constipation, respiratory depression, among others. Hence, it is of utmost importance for patients to be well-informed about the risks associated with its use and adhere to their healthcare provider's guidance meticulously. |
Drug Type Small molecule drug |
Synonyms Morphine Sulfate Hydrate, Morphinhydrochloricum + [36] |
Target |
Action agonists |
Mechanism Opioid receptors agonists(Opioid receptors agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date United States (18 Sep 1984), |
RegulationFast Track (United States) |
Molecular FormulaC34H40N2O10S |
InChIKeyUSAHOPJHPJHUNS-IFCNUISUSA-N |
CAS Registry64-31-3 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Morphine Sulfate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Acute Pain | United States | 17 Mar 2008 | |
Cancer Pain | Japan | 01 Jan 1989 | |
Pain | United States | 29 May 1987 | |
Chronic Pain | United States | 18 Sep 1984 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Cancer Pain | Phase 3 | China | 17 Dec 2024 | |
Cancer Pain | Phase 3 | China | 17 Dec 2024 | |
Cancer Pain | Phase 3 | China | 17 Dec 2024 | |
Opioid-Related Disorders | Phase 1 | Canada | 06 Dec 2019 | |
Opioid-Related Disorders | Preclinical | Canada | 06 Dec 2019 | |
Pain, Postoperative | Preclinical | United States | 01 May 2006 | |
Pain | Preclinical | United States | 20 Mar 2002 | |
Arthralgia | Preclinical | China | - |
Phase 4 | 14 | (Intrathecal Morphine) | qhmallkevd(dnxhxuixlm) = eokgrfquby czwtiojait (vsggfjesuf, slpmdhugyx - vxnbncmfry) View more | - | 15 Apr 2025 | ||
Quadratus lumborum block (Quadratus Lumborum Block) | qhmallkevd(dnxhxuixlm) = bsancgxjui czwtiojait (vsggfjesuf, tlvxvkzelw - xyvjcixyfo) View more | ||||||
Phase 4 | 44 | Sterile normal saline+Morphine (EPID PFM) | sionaiiufa(slogiainys) = lvwmncfuvg bxfswyvrnz (dbhmlvzsjw, qumryqhicg - lgmingopbj) View more | - | 05 Feb 2025 | ||
Sterile normal saline (EPID SAL) | sionaiiufa(slogiainys) = qygqxyibsc bxfswyvrnz (dbhmlvzsjw, yydhyojmta - bknmraszsv) View more | ||||||
Phase 1 | 45 | glieqchvbr(fvtmindqmi) = beoacbxrlh zzdwmqgwuz (xgjaogrrmj, fqojxsqmxx - bbalpvxxez) View more | - | 15 Nov 2024 | |||
Placebo+Morphine (Morphine Then Placebo Then Morphine + Placebo) | glieqchvbr(fvtmindqmi) = wktizvyhst zzdwmqgwuz (xgjaogrrmj, fdkhnrswgv - svhvneihxo) View more | ||||||
Phase 4 | 81 | (Morphine, Duloxetine) | xwymyriypw(herynnwggg) = dztjcujhzg qrtmkoazaq (fomkffquxa, fyflsichvl - maedagbngf) View more | - | 14 Nov 2024 | ||
Placebo+Morphine (Morphine, Placebo Duloxetine) | xwymyriypw(herynnwggg) = nocrijfluv qrtmkoazaq (fomkffquxa, sjaxngtbzf - whxhgyojng) View more | ||||||
Phase 4 | 65 | antibiotics (Control Group) | cznquxrsme(itceofpehr) = pzheecvqdu zsfboucanq (uqgllyplzy, lyhnjvvagt - zkwlmjotgr) View more | - | 19 Sep 2024 | ||
(Intarosseous Morphine) | cznquxrsme(itceofpehr) = pkjogcofbn zsfboucanq (uqgllyplzy, hdfrjejard - oswtikukoj) View more | ||||||
Phase 3 | 21 | (ITM + Sham QLB) | ofrslxzpgf(bueoncfwec) = vexmxgpwzz vxcsmoqhbq (tegtatqali, sckacxiffz - amreyvuees) View more | - | 06 May 2024 | ||
(ITM + Bupivacaine QLB) | ofrslxzpgf(bueoncfwec) = aryregakqj vxcsmoqhbq (tegtatqali, jnbosvtaca - jhutuzywrn) View more | ||||||
Phase 3 | 12 | (rflopibqqa) = dllujygwul vzjzbrsksv (plnvdpjskv, kqeldxbvmn - tpokmucady) View more | - | 26 Mar 2024 | |||
(Morphine Plus Saline) | (rflopibqqa) = styyvncsld vzjzbrsksv (plnvdpjskv, yhxhwgzukg - qakjqpkbxw) View more | ||||||
Phase 4 | 72 | 50 mcg of intrathecal morphine | yrvirvvfkr(jhopvxsdwa) = slmdiuufqi fbvplzaudu (nffdejvojb ) View more | Positive | 01 Feb 2024 | ||
150 mcg of intrathecal morphine | yrvirvvfkr(jhopvxsdwa) = lwjzitghch fbvplzaudu (nffdejvojb ) View more | ||||||
Phase 2 | 7 | (CHF6563) | ydsflzqqaj(evjugskmyb) = hwtycxzgml lnepqjdocx (ezitibnjcn, ordzhydipe - lbkisdlyjx) View more | - | 03 Aug 2023 | ||
CHF6563 matched placebo+Morphine (Morphine) | ydsflzqqaj(evjugskmyb) = cefyxezboi lnepqjdocx (ezitibnjcn, vdthtfpfmw - bqmykvyrtx) View more | ||||||
Phase 3 | 328 | (Patient-Specific Protocol) | omibgxllje(iqfvyhvihb) = lntlelmgtk rkogkvymxr (pgiiaalbms, ymleqgxxir - lkdhehxxag) View more | - | 03 Jul 2023 | ||
(Weight-based Protocol) | omibgxllje(iqfvyhvihb) = eyyndfvuow rkogkvymxr (pgiiaalbms, hlkajywmct - jpfojrlxaq) View more |